u/Born2Vanderbilt · 359d agono track record yet
Why $FEMY is a longterm pick
Femasys' FemBloc is a first-in-class non-surgical permanent birth control device with strong revenue potential if it captures even 1% of the addressable market (~$150M annually), supported by insurance coverage incentives and European partnerships. Phase 3 trial completion in April 2027 could unlock significant upside for this micro-cap biotech.
At post $11.94Now $2.04-83.0% since posted26m ago
1d+8.7%
3d+2.7%
1w-7.7%
1m+74.2%
3m-0.3%
6m-28.0%
1y—